Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Claudin-10 is an integral membrane protein of the claudin family, primarily involved in forming tight junctions that regulate the paracellular passage of ions and solutes between epithelial and endothelial cells[3]. The protein has several alternatively spliced isoforms, the two most functionally significant being claudin-10a (primarily in the kidney cortex; forms selective anion channels) and claudin-10b (widely expressed; forms selective cation channels)[1][2]. Claudin-10 is essential for epithelial barrier integrity and plays specialized roles in renal electrolyte handling and organ-specific epithelial development, such as in tooth amelogenesis. Mutations in CLDN10 are causative for HELIX syndrome, characterized by hypohidrosis, electrolyte imbalance, and ectodermal defects including enamel hypoplasia, highlighting its importance in ion homeostasis and tissue differentiation[1]. Expression deregulation in tumors may have prognostic value, but direct drug targeting and corresponding therapy are not established to date[3].
Not applicable (no approved targeting drugs); Claudin-10 modulates paracellular ion selectivity, and alterations primarily result from genetic mutations[1][2]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Claudin-10 (CLDN10).